> top > docs > PMC:3218875 > spans > 24788-25071 > annotations

PMC:3218875 / 24788-25071 JSONTXT

Annnotations TAB JSON ListView MergeView

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T13554 127-131 VBP denotes show
T13578 282-283 . denotes .
T13577 281-282 -RRB- denotes )
T13576 272-281 NN denotes rituximab
T13575 271-272 -LRB- denotes (
T13574 261-270 NN denotes depletion
T13573 254-260 NNP denotes B-cell
T13572 251-253 IN denotes as
T13571 246-250 JJ denotes such
T13570 235-245 NNS denotes treatments
T13569 232-234 TO denotes to
T13568 223-231 NN denotes response
T13567 219-222 CC denotes and
T13566 210-218 NNS denotes features
T13565 201-209 JJ denotes systemic
T13564 199-200 , denotes ,
T13563 189-199 NN denotes production
T13562 176-188 JJ denotes autoantibody
T13561 174-175 , denotes ,
T13560 163-174 NN denotes involvement
T13559 157-162 JJ denotes joint
T13558 154-156 IN denotes in
T13557 146-153 VBP denotes overlap
T13556 137-145 JJ denotes clinical
T13555 132-136 DT denotes some
T13553 118-126 NNS denotes diseases
T13552 114-117 CD denotes two
T13551 110-113 DT denotes the
T13550 107-109 IN denotes as
T13549 98-106 VBN denotes expected
T13548 95-97 VB denotes be
T13547 89-94 MD denotes might
T13546 84-88 NN denotes loci
T13545 69-83 NN denotes susceptibility
T13544 66-68 NNP denotes RA
T13543 62-65 CC denotes and
T13542 48-61 NNS denotes erythematosus
T13541 42-47 NN denotes lupus
T13540 33-41 JJ denotes systemic
T13539 25-32 IN denotes between
T13538 17-24 VBP denotes overlap
T13537 14-16 IN denotes of
T13536 7-13 NN denotes degree
T13535 2-6 JJ denotes high
T13534 0-1 DT denotes A
R9085 T13534 T13536 det A,degree
R9086 T13535 T13536 amod high,degree
R9087 T13536 T13549 nsubjpass degree,expected
R9088 T13537 T13536 prep of,degree
R9089 T13538 T13537 pobj overlap,of
R9090 T13539 T13538 prep between,overlap
R9091 T13540 T13542 amod systemic,erythematosus
R9092 T13541 T13542 compound lupus,erythematosus
R9093 T13542 T13539 pobj erythematosus,between
R9094 T13543 T13542 cc and,erythematosus
R9095 T13544 T13545 compound RA,susceptibility
R9096 T13545 T13546 compound susceptibility,loci
R9097 T13546 T13542 conj loci,erythematosus
R9098 T13547 T13549 aux might,expected
R9099 T13548 T13549 auxpass be,expected
R9100 T13549 T13549 ROOT expected,expected
R9101 T13550 T13554 mark as,show
R9102 T13551 T13553 det the,diseases
R9103 T13552 T13553 nummod two,diseases
R9104 T13553 T13554 nsubj diseases,show
R9105 T13554 T13549 advcl show,expected
R9106 T13555 T13557 det some,overlap
R9107 T13556 T13557 amod clinical,overlap
R9108 T13557 T13554 dobj overlap,show
R9109 T13558 T13557 prep in,overlap
R9110 T13559 T13560 amod joint,involvement
R9111 T13560 T13558 pobj involvement,in
R9112 T13561 T13557 punct ",",overlap
R9113 T13562 T13563 compound autoantibody,production
R9114 T13563 T13557 conj production,overlap
R9115 T13564 T13563 punct ",",production
R9116 T13565 T13566 amod systemic,features
R9117 T13566 T13563 conj features,production
R9118 T13567 T13566 cc and,features
R9119 T13568 T13566 conj response,features
R9120 T13569 T13568 prep to,response
R9121 T13570 T13569 pobj treatments,to
R9122 T13571 T13572 amod such,as
R9123 T13572 T13570 prep as,treatments
R9124 T13573 T13574 compound B-cell,depletion
R9125 T13574 T13572 pobj depletion,as
R9126 T13575 T13574 punct (,depletion
R9127 T13576 T13574 appos rituximab,depletion
R9128 T13577 T13574 punct ),depletion
R9129 T13578 T13549 punct .,expected

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T13089 281-282 -RRB- denotes )
T13088 272-281 NN denotes rituximab
T13087 271-272 -LRB- denotes (
T13086 261-270 NN denotes depletion
T13085 254-260 NN denotes B-cell
T13084 251-253 IN denotes as
T13083 246-250 JJ denotes such
T13082 235-245 NN denotes treatments
T13081 232-234 TO denotes to
T13080 223-231 NN denotes response
T13079 219-222 CC denotes and
T13078 210-218 NN denotes features
T13077 201-209 JJ denotes systemic
T13076 199-200 -COMMA- denotes ,
T13075 189-199 NN denotes production
T13074 176-188 NN denotes autoantibody
T13073 174-175 -COMMA- denotes ,
T13072 163-174 NN denotes involvement
T13071 157-162 JJ denotes joint
T13070 154-156 IN denotes in
T13069 146-153 NN denotes overlap
T13068 137-145 JJ denotes clinical
T13067 132-136 DT denotes some
T13066 127-131 VB denotes show
T13065 118-126 NN denotes diseases
T13064 114-117 CD denotes two
T13063 110-113 DT denotes the
T13062 107-109 IN denotes as
T13061 98-106 VB denotes expected
T13060 95-97 VB denotes be
T13059 89-94 MD denotes might
T13058 84-88 NN denotes loci
T13057 69-83 NN denotes susceptibility
T13056 66-68 NN denotes RA
T13055 62-65 CC denotes and
T13054 48-61 NN denotes erythematosus
T13053 42-47 NN denotes lupus
T13052 33-41 JJ denotes systemic
T13051 25-32 IN denotes between
T13050 17-24 NN denotes overlap
T13049 14-16 IN denotes of
T13048 7-13 NN denotes degree
T13047 2-6 JJ denotes high
T13046 0-1 DT denotes A
R8686 T13048 T13046 arg1Of degree,A
R8687 T13048 T13047 arg1Of degree,high
R8688 T13048 T13049 arg1Of degree,of
R8689 T13048 T13051 arg1Of degree,between
R8690 T13048 T13059 arg1Of degree,might
R8691 T13048 T13060 arg1Of degree,be
R8692 T13048 T13061 arg2Of degree,expected
R8693 T13050 T13049 arg2Of overlap,of
R8694 T13054 T13052 arg1Of erythematosus,systemic
R8695 T13054 T13053 arg1Of erythematosus,lupus
R8696 T13054 T13055 arg1Of erythematosus,and
R8697 T13055 T13051 arg2Of and,between
R8698 T13058 T13055 arg2Of loci,and
R8699 T13058 T13056 arg1Of loci,RA
R8700 T13058 T13057 arg1Of loci,susceptibility
R8701 T13061 T13059 arg2Of expected,might
R8702 T13061 T13060 arg2Of expected,be
R8703 T13061 T13062 arg1Of expected,as
R8704 T13065 T13063 arg1Of diseases,the
R8705 T13065 T13064 arg1Of diseases,two
R8706 T13065 T13066 arg1Of diseases,show
R8707 T13066 T13062 arg2Of show,as
R8708 T13066 T13070 arg1Of show,in
R8709 T13069 T13066 arg2Of overlap,show
R8710 T13069 T13067 arg1Of overlap,some
R8711 T13069 T13068 arg1Of overlap,clinical
R8712 T13072 T13071 arg1Of involvement,joint
R8713 T13072 T13073 arg1Of involvement,","
R8714 T13073 T13076 arg1Of ",",","
R8715 T13075 T13073 arg2Of production,","
R8716 T13075 T13074 arg1Of production,autoantibody
R8717 T13076 T13079 arg1Of ",",and
R8718 T13078 T13076 arg2Of features,","
R8719 T13078 T13077 arg1Of features,systemic
R8720 T13079 T13070 arg2Of and,in
R8721 T13080 T13079 arg2Of response,and
R8722 T13080 T13081 arg1Of response,to
R8723 T13082 T13081 arg2Of treatments,to
R8724 T13082 T13084 arg1Of treatments,as
R8725 T13084 T13083 arg1Of as,such
R8726 T13086 T13084 arg2Of depletion,as
R8727 T13086 T13085 arg1Of depletion,B-cell
R8728 T13086 T13087 arg1Of depletion,(
R8729 T13088 T13087 arg2Of rituximab,(
R8730 T13089 T13087 arg3Of ),(

GO-CC

Id Subject Object Predicate Lexical cue
T13151 256-260 http://purl.obolibrary.org/obo/GO_0005623 denotes cell

sentences

Id Subject Object Predicate Lexical cue
T12653 0-283 Sentence denotes A high degree of overlap between systemic lupus erythematosus and RA susceptibility loci might be expected as the two diseases show some clinical overlap in joint involvement, autoantibody production, systemic features and response to treatments such as B-cell depletion (rituximab).
T137 0-283 Sentence denotes A high degree of overlap between systemic lupus erythematosus and RA susceptibility loci might be expected as the two diseases show some clinical overlap in joint involvement, autoantibody production, systemic features and response to treatments such as B-cell depletion (rituximab).

ICD10

Id Subject Object Predicate Lexical cue
T13142 42-61 http://purl.bioontology.org/ontology/ICD10/L93 denotes lupus erythematosus
T13139 33-61 http://purl.bioontology.org/ontology/ICD10/M32 denotes systemic lupus erythematosus
T13136 33-61 http://purl.bioontology.org/ontology/ICD10/M32.9 denotes systemic lupus erythematosus

bionlp-st-ge-2016-test-ihmc

Id Subject Object Predicate Lexical cue
T13956 176-199 Gene_expression denotes autoantibody production
T13938 272-281 Entity denotes rituximab
T13904 176-188 Protein denotes autoantibody
T13894 254-260 Entity denotes B-cell
T13891 66-68 Protein denotes RA
R9285 T13904 T13956 themeOf autoantibody,autoantibody production